Patents Examined by Misook Yu
  • Jagged-binding agents and uses thereof
    Patent number: 9416178
    Abstract: The present invention relates to Jagged-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of human Jagged1 or human Jagged2 and modulate Jagged activity. The present invention further provides methods of using agents that modulate the activity of Jagged, such as antibodies that specifically bind Jagged, and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: August 16, 2016
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
  • Androgen receptor-dependent gene expression control
    Patent number: 9370499
    Abstract: Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: June 21, 2016
    Assignee: UNIVERSITAETSKLINIKUM FREIBURG
    Inventors: Roland Schuele, Eric Metzger
  • Mutant smoothened and methods of using the same
    Patent number: 9321823
    Abstract: The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: April 26, 2016
    Assignees: Genentech, Inc., Curis, Inc.
    Inventors: Frederic J. de Sauvage, Gerrit J.P. Dijkgraaf, Thomas Januario, Robert L. Yauch
  • Recombinant production of mixtures of antibodies
    Patent number: 9303081
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: April 5, 2016
    Assignee: Merus B.V.
    Inventors: Patricius H. C. Van Berkel, Ronald Hendrik Brus, Ton Logtenberg, Abraham Bout
  • IL-1 binding proteins
    Patent number: 9303085
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 5, 2016
    Assignee: ABBVIE INC.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • Alpha emitting constructs and uses thereof
    Patent number: 9289519
    Abstract: The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: March 22, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A Scheinberg, Michael R McDevitt, Dangshe Ma, George Sgouros
  • Siglec-9 binding agents
    Patent number: 9265826
    Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: February 23, 2016
    Assignee: University Court of the University of Dundee
    Inventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
  • RNA-guided human genome engineering
    Patent number: 9260723
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: February 16, 2016
    Assignee: President and Fellows of Harvard College
    Inventors: Prashant G. Mali, George M. Church, Luhan Yang
  • Methods for in vitro maturation of ovarian follicles
    Patent number: 9259438
    Abstract: The invention relates to methods to be used in the maturation of ovarian follicles and oocytes. More specifically, the invention concerns the use of inhibitors of the phosphatase PTEN, such as oxovanadate and peroxovanadate complexes, in methods for in vitro and in vivo maturation of follicles and oocytes.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: February 16, 2016
    Inventor: Kui Liu
  • Identification of surface-associated antigens for tumor diagnosis and therapy
    Patent number: 9255131
    Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: February 9, 2016
    Assignee: GANYMED PHARMACEUTICALS AG
    Inventors: Özlem Türeci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schlüter, Dirk Usener, Philippe Thiel, Michael Koslowski
  • Antibodies directed to HER-3 and uses thereof
    Patent number: 9249230
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: February 2, 2016
    Assignees: U3 Pharma GmbH, Amgen Inc.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Susanne Hartmann, Larry L. Green
  • Immunity to folate receptors
    Patent number: 9243033
    Abstract: This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FR? immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: January 26, 2016
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Keith L. Knutson, Lynn C. Hartmann, Kimberly R. Kalli, Christopher J. Krco
  • Methods of inducing and preventing neurofibromatosis in Schwann cells
    Patent number: 9226920
    Abstract: The invention provides a method of inducing neurofibromatosis type 2 (NF2) in Schwann cells. The method comprises contacting the cells with laminin-1 so as to bind ?6?1 integrin sufficiently to activate endogenous kinase Cdc42-Pak; and phosphorylating Schwannomin-S518 in the cells by the activated kinase, effectively inactivating Schwannomin's tumor suppressor activity and allowing proliferation of subconfluent Schwann cells, thereby modeling NF2. The invention also includes a method of preventing a Schwann cell from forming a tumor by contacting the cell with an amount of tyrphostin AG825 sufficient to inhibit a receptor selected from ErB2, ErB3, ?1 integrins and combinations thereof, so as to prevent phosphorylation of Schwannomin-S815 by one or more endogenous kinases.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: January 5, 2016
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Cristina Fernandez-Valle, Courtney Thaxton, Jorge Lopera, Marga Bott
  • Method of modulating the proliferation of medullary thyroid carcinoma cells
    Patent number: 9220760
    Abstract: The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. A somatostatin receptor antagonist having the formula Cpa-cyclo(D-Cys-4-Pal-D-Trp-Lys-Thr-Cys)-Nal-NH2 is also disclosed.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: December 29, 2015
    Assignee: The Administrators of the Tulane Educational Fund
    Inventor: David H. Coy
  • Therapeutic CD47 antibodies
    Patent number: 9221908
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: December 29, 2015
    Assignee: Vasculox, Inc.
    Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
  • Dual variable region antibody-like binding proteins having cross-over binding region orientation
    Patent number: 9221917
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 29, 2015
    Assignee: SANOFI
    Inventors: Nicolas Baurin, Chirstian Biel, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Methods for treating colorectal cancer
    Patent number: 9217032
    Abstract: The present disclosure is directed to methods of treating and preventing colorectal cancer metastasis or recurrence of colorectal cancer with compositions comprising anti-progastrin antibodies.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: December 22, 2015
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Julie Pannequin, Leïla Houhou, Bérénice Framery, Nejla Erkilic, Dominique Joubert, Frédéric Hollande
  • Means and methods for treating DLBCL
    Patent number: 9192665
    Abstract: The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: November 24, 2015
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Dirk Nagorsen, Juergen Scheele
  • Pharmaceutical composition
    Patent number: 9186411
    Abstract: The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. According to the present invention, a pharmaceutical composition can be stabilized by containing a nonpeptidic pharmaceutically active ingredient having a primary or secondary amino group, an excipient and an acidic compound. In addition, a solid preparation containing a pharmaceutically active ingredient, titanium oxide, a plasticizer and a chain organic acid can enhance the stability of the pharmaceutically active ingredient during light irradiation.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: November 17, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasuhiro Hiraishi, Muneo Nonomura
  • Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
    Patent number: 9173891
    Abstract: Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an amino acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: November 3, 2015
    Assignee: Angiochem, Inc.
    Inventors: Jean-Paul Castaigne, Michel Demeule, Betty Lawrence